WEBULL
WebtradeDownload

Qiagen (QGEN) Stock Could Be A Bargain Despite Its 14% Three Year Gain

Simply Wall St · 2d ago

Qiagen shares have delivered a 13.8% gain over the past three years, while the business continues to invest in new diagnostic platforms and lab automation tools. That mix of steady shareholder return and product expansion raises a simple question for investors who focus on cash flow: whether the current share price is supported by the cash the company is expected to generate.

  • The 13.8% return over three years puts real weight on whether Qiagen’s cash generation profile can justify the journey the stock has already taken.
  • Recent launches like the QIAstat-Dx bloodstream infection panels and the compact QIAmini system can influence expectations for future cash flows by shaping how quickly Qiagen turns its installed base and new instruments into recurring consumables revenue.
  • What if you looked at Qiagen through its earnings instead? See why Qiagen's 22.7x P/E tells a different valuation story.

The issue now is whether Qiagen’s current market value is aligned with the intrinsic value suggested by its cash flows under the Discounted Cash Flow (DCF) approach.

If you are evaluating Qiagen through the lens of its cash flows, it may be helpful to compare it with other businesses identified using the same quality and value criteria via 32 high quality undervalued stocks.

Is Qiagen a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses Qiagen’s free cash flow to equity as the starting point. Over the last twelve months, Qiagen generated around $459.8 million in free cash flow, and the projections used in this DCF assume growing cash flows through the next decade rather than a shrinking profile. That pattern aligns with a business that is still investing in its platform while already producing material surplus cash.

The projections in this DCF suggest those future cash flows, when discounted back, indicate an estimated intrinsic value that is meaningfully above the current share price of $45.01. The recent FDA clearance completing the QIAstat-Dx bloodstream infection portfolio helps explain why the model assumes ongoing cash generation from a broader test menu, even if the market price has not fully reflected that cash flow outlook. Find out what Qiagen could be worth using our Discounted Cash Flow (DCF) estimate.

The Qiagen Narrative: What Would Justify Today's Price?

Qiagen’s Narratives on Simply Wall St sit between the DCF output and your own judgment by spelling out what would need to happen to growth, profitability and earnings for the share price to point meaningfully higher or lower from here, and they live on the Community page. Each scenario ties a fair value estimate to a particular mix of potential catalysts and key risks, so you can track over time which version of Qiagen's story appears to be unfolding.

Qiagen’s community splits into one camp that sees enough automation and cash discipline to justify more optimism and another that worries funding and QuantiFERON headwinds could keep a lid on things.

Bull case: roughly fairly valued

"Disciplined capital allocation that favors organic investment, bolt on deals such as Parse Biosciences and Genoox, and rising shareholder returns through a higher dividend and sizeable share repurchases…"

Discover why this Narrative puts Qiagen at roughly fairly valued.

Bear case: 12% overvalued

"A sustained reset in QuantiFERON immigration testing demand, which management now treats as a permanent reduction in the addressable pool in the U.S. and parts of the Middle East…"

Explore why this Narrative puts Qiagen at 12% overvalued.

Qiagen’s valuation still leaves one crucial piece of the puzzle unanswered

Price and cash flows tell only part of Qiagen’s story, because the internal checks on this business have raised specific concerns that deserve attention before you rely on any single fair value view. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.